Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 2013 by Prolong Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Prolong Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01374165
First received: May 26, 2011
Last updated: April 23, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given